Evidence map›Paper›PMID 28611288›Full record

ArticleOncotarget2017

An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.

Sayyed K Zaidi, Andrew W Perez, Elizabeth S White, Jane B Lian, Janet L Stein, Gary S Stein

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. An Assessment on Ethanol-Blended Gasoline/Diesel Fuels on Cancer Risk and Mortality.International journal of environmental research and public health · 2021
    Review
  4. Article
  5. MicroRNAs in Autoimmunity and Hematological Malignancies.International journal of molecular sciences · 2018
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sayyed K ZaidiDepartment of Biochemistry and University of Vermont Cancer Center, The University of Vermont Larner College of Medicine, Burlington, VT, USA.
Andrew W PerezDepartment of Biochemistry and University of Vermont Cancer Center, The University of Vermont Larner College of Medicine, Burlington, VT, USA.
Elizabeth S WhiteDepartment of Biochemistry and University of Vermont Cancer Center, The University of Vermont Larner College of Medicine, Burlington, VT, USA.
Jane B LianDepartment of Biochemistry and University of Vermont Cancer Center, The University of Vermont Larner College of Medicine, Burlington, VT, USA.
Janet L SteinDepartment of Biochemistry and University of Vermont Cancer Center, The University of Vermont Larner College of Medicine, Burlington, VT, USA.
Gary S Stein
University of Vermont · US

Funding

SUBNUCLEAR TARGETING OF TRANSCRIPTION FACTORSP01CA082834 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STEIN, GARY S. · 2001 to 2015
$18.4M
Deregulated microRNAs in Acute Myeloid LeukemiaR03CA167726 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI ZAIDI, SAYYED KALEEM · 2013 to 2014
$150k
NCI NIH HHS P01 CA082834NCI NIH HHS R03 CA167726
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is characterized by an aggressive clinical course and frequent cytogenetic abnormalities that include specific chromosomal translocations. The 8;21 chromosomal rearrangement disrupts the key hematopoietic RUNX1 transcription factor, and contributes to leukemia through recruitment of co-repressor complexes to RUNX1 target genes, altered subnuclear localization, and deregulation of the myeloid gene regulatory program. However, a role of non-coding microRNAs (miRs) in t(8;21)-mediated leukemogenesis is minimally understood. We present evidence of an interplay between the tumor suppressor miR-29b-1 and the AML1-ETO (also designated RUNX1-RUNX1T1) oncogene that is encoded by the t(8;21). We find that AML1-ETO and corepressor NCoR co-occupy the miR-29a/b-1 locus and downregulate its expression in leukemia cells. Conversely, re-introduction of miR-29b-1 in leukemia cells expressing AML1-ETO causes significant downregulation at the protein level through direct targeting of the 3' untranslated region of the chimeric transcript. Restoration of miR-29b-1 expression in leukemia cells results in decreased cell growth and increased apoptosis. The AML1-ETO-dependent differentiation block and transcriptional program are partially reversed by miR-29b-1. Our findings establish a novel regulatory circuit between the tumor-suppressive miR-29b-1 and the oncogenic AML1-ETO that controls the leukemic phenotype in t(8;21)-carrying acute myeloid leukemia.

Indexed as

Gene Expression Regulation, LeukemicAcute DiseaseApoptosisCell DifferentiationCell Line, TumorCell ProliferationChromosomes, Human, Pair 21Chromosomes, Human, Pair 8Core Binding Factor Alpha 2 SubunitCo-Repressor ProteinsHumansLeukemia, MyeloidMicroRNAsOncogene Proteins, FusionPhenotypeRUNX1 Translocation Partner 1 ProteinAML1-ETO fusion protein, humanCore Binding Factor Alpha 2 SubunitCo-Repressor ProteinsMicroRNAsMIRN29a microRNA, humanOncogene Proteins, FusionRUNX1 Translocation Partner 1 ProteinAML1-ETOleukemiamiR-29RUNXt(8;21)

Identifiers

PMID28611288
PMCPMC5522207
OpenAlexW2618521344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.